相关实验视频

Updated: Jun 11, 2025

Mechanical Stimulation-induced Calcium Wave Propagation in Cell Monolayers: The Example of Bovine Corneal Endothelial Cells

Mechanical Stimulation-induced Calcium Wave Propagation in Cell Monolayers: The Example of Bovine Corneal Endothelial Cells

Published on: July 16, 2013

乙化物通过调节TRPC1/4/6和calmodulin来抑制PASMC的过载,以防止缺氧肺动脉重塑

Enqi Zhao¹, Jinyu Wang¹, Yuefu Zhao¹

¹School of Pharmacy, Qinghai Minzu University, Xining, Qinghai, 810007, China.

Open medicine (Warsaw, Poland)

|October 9, 2024

概括

乙化 (ECH) 通过抑制肺动脉光滑肌细胞 (PASMC) 中的流入和增殖,有效治疗缺氧性肺高血压 (HPH). 这种治疗减少了肺血管改造 (PVR) 并降低了HPH大鼠模型中的肺动脉压力.

科学领域:

药理学药理学是指药理学的学科.
心血管研究研究心血管研究
细胞生物学细胞生物学

背景情况:

低毒性肺高血压 (HPH) 可能涉及交感神经系统的刺激,导致北上腺素 (NE) 诱导的过载和肺动脉光滑肌细胞 (PASMC) 的异常增殖.
这些细胞变化与肺血管改造 (PVR) 密切相关,这是HPH的一个关键特征.

研究的目的:

为了研究 Echinacoside (ECH) 在治疗 HPH 的治疗机制.
在HPH的体外和体外模型中确定ECH对流入,PASMC增殖和PVR的影响.

主要方法:

在体外:NE诱导的PASMCs被ECH治疗,以评估细胞内 ([Ca2+]cyt) 变化和扩散,使用Fluo-4 AM和流细胞计.
在体内:建立了一个HPH大鼠模型. 大鼠接受了ECH治疗,随后进行了血素和欧 (HE) 染色,以评估PVR,并对蛋白质表达进行西部斑分析.

主要成果:

ECH以度依赖的方式抑制了NE诱导的[Ca2+]细胞增加和PASMC增殖.
在PASMC中,ECH降低了短暂受体潜在通道 (TRPC) 1,TRPC4,TRPC6和calmodulin的表达.
在HPH大鼠中,ECH显著降低了肺动脉平均压力,减轻了PVR,并降低了这些关键蛋白质在肺组织中的表达.

结论:

埃奇纳科赛德在低氧性肺高血压中显示出显著的治疗潜力.
ECH通过调节信号通路和减少肺血管重塑来发挥其保护作用.

关键词:

和是最重要的.这是一种 echinacoside.低氧气的情况是这样的.肺高血压是一种肺高血压.肺血管重塑肺血管重塑

更多相关视频

Isolation of Microvascular Endothelial Tubes from Mouse Resistance Arteries

Isolation of Microvascular Endothelial Tubes from Mouse Resistance Arteries

Published on: November 25, 2013

Imaging Ca2+ Signals in Small Pulmonary Veins at Physiological Intraluminal Pressures

Imaging Ca²⁺ Signals in Small Pulmonary Veins at Physiological Intraluminal Pressures

Published on: March 21, 2025

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Antihypertensive Drugs: Action of Calcium Channel Blockers

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...